Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsCipla

    Jump to

    • Will file appeal in US court on drug patent breach: Cipla

      A US District Court has ordered the seizure of a drug made by Cipla and sold by Velecra. S Radhakrishnan, CFO, Cipla has clarified on CNBC-TV18 that they are in process of filing an appeal within the next 60 days.

    • See marginal impact on EPS, if DEPB is withdrawn: Cipla

      In an interview with CNBC-TV18, S Radhakrishnan, CFO, Cipla says, DEPB related income in FY11. He further says, the company will see marginal impact on earning per share (EPS), if the scheme is withdrawn.

    • Cipla tells Merck your anti-AIDS drug too costly in India

      Domestic pharma giant Cipla has taken the route of applying for a "voluntary license" for Merck's HIV Isentress (a generic raltegravir) saying it is not reaching needy patients in India and is prices exorbitantly.

    • New MAT levy to impact cash flows, says Cipla

      Speaking to CNBC-TV18, S Radhakrishnan, whole-time director of pharma major Cipla said new MAT charge will impact the company's cash flows.

    • Ongoing talks with MNCs not for stake sale: Cipla

      In an exclusive interview with CNBC-TV18’s Ekta Batra and Reema Tendulkar, S Radhakrishnan, Wholetime Director of Cipla denies rumours of any kind of stake sale, calling them ‘baseless’.

    • What is Lupin's acquisition agenda for the future?

      Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347